Characterization and impact of response to holding/bridging therapy in second-line large Bcell lymphoma patients treated with axicabtagene ciloleucel: a LYSA study from the French DESCAR-T registry

The optimal approach for holding or bridging therapy (H/BT) prior to second line axicabtagene ciloleucel (axi-cel) remains undefined, and the prognostic impact of response to H/BT remains debated. Here, we characterize real-world H/BT strategies and evaluate the impact of response on outcome following axi-cel infusion in the second-line setting for relapse or refractory (R/R) large B-cell lymphoma (LBCL). We included all adults with R/R LBCL within 12 months of first-line therapy who received axi-cel in the nationwide French DESCAR-T cohort (NCT04328298). The primary objective was to EFS between H/BT responders and nonresponders, as per Lugano criteria, using propensity score matching (PSM). Secondary objectives were to characterize H/BT modalities, corresponding responses, and to identify predictors of EFS at infusion. Among 566 patients included, 469 (83%) received chemotherapy-based H/BT, while 97 (17%) received a chemo-free approach, including no H/BT. Patients treated with chemotherapy-based H/BT had more advanced disease characteristics and exhibited inferior EFS compared to those receiving chemo-free approaches. After PSM, OS was significantly improved in responders versus non-responders (HR=0·70 [95% CI 0·51-0·96], p=0·0292), while the EFS benefit no longer reached statistical significance (HR=0·86 [95%CI 0·70-1·07], p=0·1739). Given that only patients ultimately receiving axi-cel were analyzed, the impact of H/BT response may have been underestimated. A predictive score combining response to H/BT, international prognostic index, LDH, and CRP at infusion identified two risk groups with significantly different EFS. In conclusion, H/BT response appears to be associated with axi-cel outcomes particularly when combined to inflammatory markers and residual LDH.

Authors

Institutions

Publication Details

Journal
Haematologica
Published
2026-11-19
DOI
https://doi.org/10.3324/haematol.2026.301559
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Characterization and impact of response to holding/bridging therapy in second-line large Bcell lymphoma patients treated with axicabtagene ciloleucel: a LYSA study from the French DESCAR-T registry

Elodie Gat, Blandine Guffroy, Aline Schmidt, Michael L. Loschi et al.
Haematologica
CAR-T cell therapy research
article

Characterization and impact of response to holding/bridging therapy in second-line large Bcell lymphoma patients treated with axicabtagene ciloleucel: a LYSA study from the French DESCAR-T registry

Elodie Gat, Blandine Guffroy, Aline Schmidt, Michael L. Loschi, Sylvain Choquet, Pierre Bories, Gabriel Brisou, Adrien Chauchet, Roch Houot, Antoine Capes, Guillaume Cartron, Catherine Thiéblemont, Amandine Durand, Stéphanie Guidez, Laure L Lebras, Franck Morschhauser, Emmanuel Bachy, Florent Malard, Guillaume Manson, Estelle Bourbon, Gandhi Laurent Damaj, Olivier Hermine, Sylvain Carras, Rémy Duléry, Laura Herbreteau, Benoît Tessoulin, Fabien Le Bras, Fabrice Jardin, Justine Decroocq, Caroline Rossoni, François‐Xavier Gros, Jacques‐Olivier Bay, Cristina Castilla Llorente, Marie‐Thérèse Rubio, Julie Abraham, Jean‐Valère Malfuson, Ludovic Fouillet, Laurianne Drieu La Rochelle, Magalie Joris, Steven Le Gouill
article en

Abstract

The optimal approach for holding or bridging therapy (H/BT) prior to second line axicabtagene ciloleucel (axi-cel) remains undefined, and the prognostic impact of response to H/BT remains debated. Here, we characterize real-world H/BT strategies and evaluate the impact of response on outcome following axi-cel infusion in the second-line setting for relapse or refractory (R/R) large B-cell lymphoma (LBCL). We included all adults with R/R LBCL within 12 months of first-line therapy who received axi-cel in the nationwide French DESCAR-T cohort (NCT04328298). The primary objective was to EFS between H/BT responders and nonresponders, as per Lugano criteria, using propensity score matching (PSM). Secondary objectives were to characterize H/BT modalities, corresponding responses, and to identify predictors of EFS at infusion. Among 566 patients included, 469 (83%) received chemotherapy-based H/BT, while 97 (17%) received a chemo-free approach, including no H/BT. Patients treated with chemotherapy-based H/BT had more advanced disease characteristics and exhibited inferior EFS compared to those receiving chemo-free approaches. After PSM, OS was significantly improved in responders versus non-responders (HR=0·70 [95% CI 0·51-0·96], p=0·0292), while the EFS benefit no longer reached statistical significance (HR=0·86 [95%CI 0·70-1·07], p=0·1739). Given that only patients ultimately receiving axi-cel were analyzed, the impact of H/BT response may have been underestimated. A predictive score combining response to H/BT, international prognostic index, LDH, and CRP at infusion identified two risk groups with significantly different EFS. In conclusion, H/BT response appears to be associated with axi-cel outcomes particularly when combined to inflammatory markers and residual LDH.

Haematologica
Hôpital Necker-Enfants Malades (FR), Université Paris-Est Créteil (FR), Centre Hospitalier Universitaire de Grenoble (FR), Institut Gustave Roussy (FR), Centre Hospitalier Universitaire de Bordeaux (FR), Centre Hospitalier Universitaire de Lille (FR), Centre Hospitalier Universitaire de Nice (FR), Centre Hospitalier Universitaire de Nantes (FR), Centre Hospitalier Universitaire Henri-Mondor (FR), Centre Hospitalier Universitaire de Toulouse (FR), Centre Hospitalier Universitaire de Besançon (FR), Hôpital Cochin (FR), Centre Hospitalier Universitaire de Montpellier (FR), Centre Hospitalier Universitaire de Tours (FR), Centre Hospitalier Universitaire Amiens-Picardie (FR), Centre Hospitalier Régional et Universitaire de Nancy (FR), Hospices Civils de Lyon (FR), Hôpital Saint-Antoine (FR), Centre Léon Bérard (FR), The Lymphoma Academic Research Organisation (FR), Centre Hospitalier Universitaire de Poitiers (FR), Centre Hospitalier Universitaire d'Angers (FR), Centre Hospitalier Universitaire de Caen Normandie (FR), CHU Dijon Bourgogne (FR), Centre Hospitalier Universitaire de Limoges (FR), Pitié-Salpêtrière Hospital (FR), Centre Hospitalier Universitaire de Clermont-Ferrand (FR), Hôpitaux Universitaires Henri-Mondor (FR), Centre Hospitalier Régional Universitaire de Brest (FR), Hôpital d'instruction des Armées Percy (FR), Hôpital Universitaire Dupuytren (FR), Hôpital Saint-Louis (FR), Hôpitaux Universitaires de Strasbourg (FR), Institut Paoli-Calmettes (FR), Centre Hospitalier Universitaire de Rennes (FR), Centre Hospitalier Universitaire de Saint-Étienne (FR), Centre Henri Becquerel (FR), Institut Curie (FR), Université Grenoble Alpes (FR)
CAR-T cell therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon